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Background: An extended left hepatectomy is a complex hepatic resection often performed for large
tumours in close relationship to major hilar structures. Operative outcomes of this resection for colorectal
liver metastases (CLM) remain unclear. The aim of the present study was to assess short- and long-term
outcome for patients with CLM after an extended left hepatectomy.
Methods: A retrospective analysis of consecutive patients undergoing an extended left hepatectomy for
CLM in a large, single-centre cohort between January 1990 and January 2006 was performed.
Results: Thirty-one patients (3.9%) from a consecutive series of 802 patients who had undergone
hepatic resection were identified as having met the definition of an extended left hepatectomy and were
included for further analysis. Maximum tumour size was more than 60 mm in 15 patients, with a median
size of 67.5 mm for the total group (range: 20 to 160 mm). Twenty-six patients presented with initially
unresectable metastases, related to large tumour size in 11 patients and to a close relation with major
vascular structures in six patients. Preoperative chemotherapy was administered to 29 patients. Com-
bined vascular resection was performed in five patients. The mortality rate at 90 days was zero and
post-operative morbidity occurred in 17 patients. R0 and R1 resections were performed in 17 and 11
patients, respectively. Three- and 5-year overall survival was 38% and 27%, respectively. Disease-free
survival was 9% and 4% at 3 and 5 years. Morbidity did not differ between patients with and without a
caudate lobectomy (9 of 17 patients vs. 8 of 14 patients, respectively) (P = 0.815).
Conclusions: An extended left hepatectomy for CLM can provide significant long-term survival.
However, morbidity is increased in this complex procedure. A caudate lobectomy does not impact
surgical outcome.
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Introduction
In current liver surgery, resections up to 70% of functional liver
volume have been shown to be safe without the risk of
post-operative liver failure.1 The most important indication for a
major hepatectomy is the presence of an extensive intrahepatic
tumour, either caused by multiple metastases or large tumour size.
Extended left hepatectomies are, however, not comparable to any
other liver resection because of their technical complexity related
to a large resection surface, central liver dissection and resection of
the caudate lobe. Nevertheless, patients with centrally located
metastases with close contact to major vascular or biliary structures
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often require an extended left hepatectomy to achieve complete
tumour clearance.
Recently, the authors have shown that major liver resections
combined with a vascular resection and reconstruction can safely
be performed in selected patients.2 However, extended left hepa-
tectomies are still suggested to have higher morbidity and mor-
tality rates compared with other resections because of the
complexity of the procedure.3–5 Yet, the inclusion of mixed patient
groups in all previous series interferes with an objective analysis of
surgical morbidity after an extended left hepatectomy in patients
with colorectal liver metastases (CLM).3,6–8 Different diseases with
various underlying pre-existing conditions, such as cirrhosis in
patients with a hepatocellular carcinoma or jaundice in patients
with hilar tumours, can all influence surgical outcome.9 Critical
analysis of associated risks and results of this challenging proce-
dure is, however, crucial when offering it to patients as a poten-
tially curative treatment.
The objective of the present study was to assess the short- and
long-term outcome for patients with CLM after an extended left
hepatectomy in a large, single-centre cohort. A secondary objec-
tive was to determine the impact of a caudate lobectomy on post-
operative morbidity.
Patients and methods
All consecutive patients who underwent an extended left hepate-
ctomy for CLM between January 1990 and January 2006 were
included. Patients were selected from a prospectively maintained
hepatobiliary database. Extended hepatectomies were defined as
resections exceeding the boundaries of a standard left hepatec-
tomy (segments II–IV).10,11 Extended left hepatectomies therefore
included segments II–IV with segment I alone, or with segments V
and VIII, or with segments I, V and VIII.
Pre-operative chemotherapy
Systemic chemotherapy was administered to patients with techni-
cally unresectable liver metastases. Initial unresectability was
defined as the inability to completely resect all liver metastases
while leaving at least 30% to 40% of functional liver volume or the
presence of extrahepatic disease. Local unresectability was defined
either by involvement of major vascular structures such that a
clear margin could not be achieved, involvement of multiple liver
segments, or large tumour size such that the future remnant liver
volume was deemed to be insufficient. During the study period,
chemotherapy was also increasingly administered to patients
with upfront resectable metastases to assess tumour chemo-
responsiveness and to facilitate margin-negative resections.
Clinical response to chemotherapy according to WHO guide-
lines12 and more recently by using the response evaluation criteria
in solid tumours (RECIST) criteria13 was assessed by computed
tomography and/or magnetic resonance imaging in a multidisci-
plinary meeting with surgeons, oncologists and radiologists every
four cycles of treatment. Surgery was considered only when com-
plete resection of intra- and extrahepatic metastases could be
achieved.
Hepatectomy
During surgery, the abdominal cavity was searched for extrahe-
patic metastases and suspicious lesions were examined by frozen
section. Intra-operative ultrasound of the liver was used in all
patients to confirm the number and size of metastases, to define
their relation with intrahepatic vascular structures and to search
for occult lesions. Liver resections were performed with the objec-
tive of radical resection, either achieved by single or multiple
procedures. When tumour-free margins could not be obtained,
owing to vascular proximity or the presence of multiple
metastases, resection was still performed provided that it was
macroscopically complete. Prophylactic abdominal drains were
placed in all patients after a hepatectomy.
Portal vein embolization (PVE) and two-stage hepatectomy
procedures were used accordingly for patients with estimated
resections of more than 60% to 70% of liver parenchyma (based
on pre-operative CT volumetrics) or with multiple metastases
unable to be resected by a single hepatectomy.14,15 PVE was per-
formed pre-operatively by a percutaneous or ileocolic technique
decided by the treating surgeon.16,17 In selected patients, portal
vein embolization and ligation was performed intra-operatively
during resection of the primary tumour or the first step of a
two-stage hepatectomy approach.15 Local ablative techniques
(RFA or cryotherapy) were only used in combination to resection
for three or less, otherwise unresectable metastases up to 3 cm in
diameter in the future remnant liver. Vascular reconstruction was
considered in cases with tumoural encasement of major vascular
structures. For these resections, total vascular exclusion of the liver
with or without venovenous bypass was generally used.2,18–20
R0 and R1 resections were defined by the absence (any tumour-
free margin) or presence (tumour-free margin 0 mm) of micro-
scopic tumour invasion of the resection margins, respectively.21
All post-operative complications occurring within 2 months
after surgery were recorded and graded according to the Dindo–
Clavien classification.22 An increase in the serum bilirubin level to
>50 mmol/l and a decrease in prothrombin time to <50% on post-
operative day 5 were used to define liver insufficiency.23 Post-
operative mortality was assessed at 90 days.
Follow-up
Regular post-operative follow-up started at 1 month from hepa-
tectomy, and then every 4 months, consisting of routine blood
tests, serum tumour markers evaluation (CEA and CA19.9) and
hepatic ultrasound. Thoracoabdominal CT imaging was per-
formed every 8 months. The general policy was to continue che-
motherapy after liver resection for six to eight cycles to reduce the
risk of recurrence. Suspicion of tumour recurrence in the case of
elevated tumour markers always necessitated radiological confir-
mation. Resection of intra- or extrahepatic disease recurrence was
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performed only when it could be globally curative and was gen-
erally preceded by chemotherapy to control the disease process.24
Statistical analysis
The c2-test was used to compare categorical data (the number
of patients with percentages) and continuous data (median with
range) were compared using the Mann–Whitney U-test for
non-parametric data. Survival curves were generated by the
Kaplan–Meier method and compared using the log-rank test.
Statistical significance was defined as P  0.05. All statistical
analyses were performed with SPSS version 13.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Between January 1990 and January 2006, a consecutive series of
802 patients underwent a partial hepatectomy for CLM with cura-
tive intent, 31 (3.9%) of which underwent an extended left hepa-
tectomy (Fig. 1). The number of extended left hepatectomies
performed between 1990–95, 1995–2000 and 2000–06 were 1, 10
and 20, respectively.
Demographics, primary and secondary tumour characteristics
and chemotherapy regimens are provided in Table 1. Maximum
tumour size was more than 60 mm at diagnosis in 15 patients.
Intra- and post-operative variables are provided in Table 2. Fifteen
patients received intra-operative red blood cell transfusions.
In two patients with concomitant extrahepatic disease, lung
metastases were scheduled to be resected after curative liver
surgery. However, disease progression unable to be controlled by
chemotherapy prevented lung surgery in both patients.
An R0, R1 and R2 margin occurred in 17, 11 and 0 patients,
respectively. For three patients these data was missing. PVE did
not affect the incidence of R1 resections (2 of 6 patients in the PVE
group vs. 9 of 25 in the no PVE group) (P = 0.971).
Tumour recurrence was diagnosed in 26 patients after a median
follow-up of 24.9 months (range: 6.0 to 85.2 months) for the total
group. Median time to first recurrence was 9.8 months (range: 1.0
to 43.6 months). Intrahepatic recurrences occurred in 15 patients,
which in seven patients were combined with extrahepatic recur-
rence. Three patients underwent a second liver resection. Local-
ized extrahepatic disease recurrence was resected once in five
patients, twice in one patient and three times in one patient.
At last follow-up, 20 patients have died, 4 patients are alive and
7 patients are lost to follow-up. Three- and 5-year overall survivals
for the total group of 31 patients were 38% and 27%, respectively
(Fig. 2). Overall survival did not differ according to R0-R1 status
All patients who underwent a hepatectomy
for colorectal metastases
(January 1990 to January 2006)
n = 802
Major hepatectomy
n = 364 (45%) 
Minor hepatectomy
n = 438 (55%) 
Other major
 hepatectomy
n = 41 (5%) 
Left-sided
 hepatectomy
n = 83 (10%) 
Right-sided
 hepatectomy
n = 240 (30%) 
Standard
n = 176 (22%) 
Standard
n = 52 (6%) 
Extended
n = 64 (8%) 
Extended
n = 31 (4%) 
Figure 1 Flowchart of patient selection. Standard right hepatectomies include segments V–VIII, and extended right hepatectomies include
segments V–VIII with segment IV, segment I, or both. Standard left hepatectomies include segments II–IV, and extended left hepatectomies
include segments II–IV with segment I, segments V and VIII or segments I, V and VIII
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Table 1 Patient, tumour and chemotherapy characteristics
Extended left
hepatectomy
(n = 31)
Patients
Median age (range), years 59.5 (42–79)
Male/female 17 / 14
Primary tumour
Colon/rectum 25 / 6
T stage
1/2 1
3/4 21
N stage
0 8
1/2 15
Liver metastases
Synchronousa 18
Median number (range) 3 (1–20)
3 15
>3 13
Median size (range), mm 67.5 (20–160)
Bilobar 26
Initially unresectable 26
Cause of initial unresectability
Multiple metastases 8
Large tumour size 11
Close vascular relationship 6
Extrahepatic disease 1
Concomitant extrahepatic disease 5
Resection 3
Pre-operative chemotherapy 29
Number of lines
1 21
>1 8
Median number of cycles (range) 8 (3–27)
Last line regimen
5-FU/LV 1
5-FU/LV Oxaliplatin 19
5-FU/LV Irinotecan 5
Other 4
Clinical response
Complete 0
Partial 19
Stabilization 8
Progression 2
aSynchronous metastases were diagnosed before or within 3 months
after resection of the primary colorectal tumour.
SD, standard deviation; 5-FU, 5-fluorouracil; LV, leucovorin.
Table 2 Data concerning liver resection and short-term outcome
Extended left
hepatectomy
(n = 31)
Median number of detected metastases (range) 2 (1–14)
1 6
2–3 12
>3 11
Resection type
Anatomical 13
Anatomical and non-anatomical 18
Vascular occlusion 29
Pedicular clamping 19
Vascular exclusion 9
Selective 1
Vascular resection and reconstruction 5
Portal vein 2
Inferior vena cava 1
Hepatic vein 2
Combined local treatment
None 28
RFA 2
Cryotherapy 1
Two-stage resection 1
Portal vein embolization 6
Median red blood cell transfusions (range), units 1 (0–28)
Mortality (90 days) 0
Morbidity 17
General complicationsa 7
Hepatic complications 13
Biliary leak 2
Haemorrhage 0
Infected collection 3
Non-infected collection 6
Liver insufficiency23 2
Dindo–Clavien classification22
Grade I/II 5
Grade III/IV 7
Relaparotomy 2
Percutaneous drainage 7
Median hospital stay (range), days 13 (8–31)
Post-operative chemotherapyb 27
aAs general complications were considered: pulmonary, cardiovascular,
urinary tract, infectious (other than local hepatic) and iatrogenic
complications.
bAdjuvant chemotherapy after liver resection.
SD, standard deviation; RFA, radiofrequency ablation.
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(36% and 54% at 3 years, respectively) (P = 0.165) or the presence
of extrahepatic disease (26% and 41% at 3 years with and without
extrahepatic disease, respectively) (P = 0.491). Disease-free sur-
vivals at 3 and 5 years were 9% and 4%, and were also not related
to R0-R1 status (6% and 16% at 3 years, respectively) (P = 0.810).
Caudate lobectomy
Out of all 31 patients that underwent an extended left hepatec-
tomy, 17 also had resection of the caudate lobe (segment I).
Patient groups with and without a caudate lobectomy were similar
in terms of age, gender distribution, primary and secondary
tumour characteristics and chemotherapy treatment (Table 3).
Of all five patients that underwent vascular resection and recon-
struction in the total group, four had resection of the caudate lobe
(P = 0.217). Total vascular exclusion was used in six patients with a
caudate lobectomy and in three patients without a caudate lobec-
tomy (P = 0.338). Intra-operative red blood cell transfusions were
necessary in 10 patients that underwent a caudate lobectomy (com-
pared with five patients in the control group) (P = 0.198).
Post-operative morbidity occurred in nine and eight patients
with and without a caudate lobectomy, respectively (P = 0.815).
Although R1 resections were more frequent in the caudate lobec-
tomy group because of vascular proximity of the metastases (8 vs
3 patients) (P = 0.102), recurrences occurred in a similar propor-
tion of patients in both groups (in 14 and 12 patients with and
without caudate lobectomy, respectively) (P = 0.886).
Discussion
Owing to significant development of surgical techniques as well as
extended indications for a partial hepatectomy in patients with
CLM, major hepatectomies are now increasingly being per-
formed. Extended left hepatectomies, however, represent a specific
category of liver surgery owing to the technical difficulty related to
the dissection of hilar structures as well as resection of the caudate
lobe. Until now, specific analysis of short-term outcome of
this procedure in a sufficient cohort of patients with CLM was
lacking.3,4,7,8
The main result of the present study is that extended left hepa-
tectomies for patients with CLM can result in significant long-
term survival. Three-year survival could be achieved in 38% of
patients, not so different from general survival rates reported in
the literature.25–27 Post-operative mortality was nil, with however a
significant morbidity rate. Of note, disease-free survival was only
9% at 3 years and 4% at 5 years. A possible explanation is the
frequency of R1 resections associated with this type of resection
(11 of 31 patients) and a high incidence of disease recurrence. For
metastases in close contact to vascular structures, tumour-free
resection margins are often impossible to achieve. Nevertheless,
overall survival was not influenced by a R1 resection. As previ-
ously reported, in the current era of effective chemotherapy with
the possibility of a repeat hepatectomy, R1 resections do not affect
survival.28 This furthermore confirms the value of extended left
hepatectomy for patients with complex metastases otherwise
unresectable. Complete macroscopic removal of all lesions
remains, however, essential.14,15
Previous reports describing extended left hepatic resections all
included mixed populations of patients with cholangiocarcino-
mas (including patients with jaundice), hepatocellular carcinomas
(usually in cirrhotic patients) and colorectal metastases.3,4,7,8
Owing to the inclusion of small patient numbers, information on
morbidity and mortality rates for patients with CLM is absent or
Overall survival (n = 31)
Disease-free survival (n = 30)
38%
27%
4%
9%
Years
S
ur
vi
va
l
1
0.8
0.6
0.4
0.2
0
0 1 2 3 4 5
Patients at risk Total
Overall survival
Disease-free survival
1 yr 2 yrs 3 yrs 4 yrs 5 yrs
31 26 16 7 6 4
11281630
Figure 2 Overall- and disease-free survival curves after an extended left hepatectomy for colorectal liver metastases (CLM)
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very limited. The present study, to the authors’ knowledge, is the
first to specifically address short-term outcome of an extended left
hepatectomy in a homogeneous group of patients with CLM only.
Patients usually had central, large metastases in close relation
with major hilar structures, reflecting the technical complexity of
this procedure. Resection of centrally located metastases in close
proximity with main vascular structures often needs vascular
resection and reconstruction with total vascular exclusion to
control intra-operative blood loss. Therefore, operative character-
istics of extended left liver resections generally differ from those of
Table 3 Comparison of patient, tumour and chemotherapy characteristics between groups with and without a caudate lobectomy
With a caudate lobectomy
(n = 17)
Without a caudate lobectomy
(n = 14)
P
Patients
Median age (range), years 61.7 (42–79) 56.8 (45–72) 0.874
Male/female 10 / 7 7 / 7 0.623
Primary tumour
Colon/rectum 15 / 2 10 / 4 0.239
T stage
1/2 1 0 0.439
3/4 13 8
N stage
0 5 3 0.842
1/2 10 5
Liver metastases
Synchronousa 9 9 0.524
Median number (range) 2 (1–8) 4 (1–20) 0.287
3 9 6 0.743
>3 7 6
Median size (range), mm 70.0 (20–160) 67.5 (20–100) 0.328
Bilobar 13 13 0.217
Initially unresectable 16 10 0.087
Cause of initial unresectability
Multiple metastases 5 3 0.386
Large tumour size 6 5
Close vascular relationship 5 1
Extrahepatic disease 0 1
Concomitant extrahepatic disease 4 1 0.217
Resection 2 1 0.361
Pre-operative chemotherapy 16 13 0.887
Number of lines
1 12 9 0.730
>1 4 4
Median number of cycles (range) 8 (4–18) 10 (3–27) 0.320
Last line regimen
5-FU/LV 0 1 0.711
5-FU/LV Oxaliplatin 11 8
5-FU/LV Irinotecan 3 2
Other 2 2
Clinical response
Complete/partial 11 8 0.913
Stabilization/progression 6 4
aSynchronous metastases were diagnosed before or within 3 months after resection of the primary colorectal tumour.
SD, standard deviation; 5-FU, 5-fluorouracil; LV, leucovorin.
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major right-sided resections. In a natural way, colorectal liver
metastases are most frequently located in the right lobe, owing to
anatomical differences in weight and portal venous inflow of both
hemilivers.29,30 This natural distribution of metastases results in a
tumour presentation which is more often multifocal in patients
selected for a right hepatectomy. Right-sided resections usually
include more liver segments, and additional strategies such as PVE
and two-stage approaches are more frequently required to achieve
complete tumour resection. Indeed, the authors’ recent report
describing the results of PVE also mainly included right-sided
resections.14 On the contrary, vascular resection is much less fre-
quently performed in extended right hepatectomies (8% of
patients in the authors’ own series; data not shown).
Biliary leakage and (non)infected collections occurred fre-
quently in this series. Previous reports also found that bile leakage
was a frequent complication in left hepatectomy patients because
of the difficult parenchymal transection.3,4,7 The high incidence of
collections could be related to the difficulty to have an efficient
drainage after a left-sided hepatectomy compared with right-sided
resections. Patients undergoing right hepatectomies have a higher
incidence of post-operative liver insufficiency because of the
resection of higher liver volumes.14,15 In combination with massive
pre-operative chemotherapy, the risk of liver failure is known to
be elevated.31,32 Post-operative liver insufficiency, on the other
hand, occurred only in two patients in the present study.
Liver metastases involving the caudate lobe add to the complex-
ity of a curative hepatectomy caused by its difficult anatomical
localization. The caudate lobe lies in close relation with the infe-
rior vena cava, the portal bifurcation and the confluence of the left
and middle hepatic veins.33 Its mobilization from the inferior vena
cava with the ligation of its short hepatic veins during resection
increases the risk of intra-operative blood loss and associated
morbidity. However, owing to surgical refinements, resection of
the caudate lobe is increasingly performed.34 The fact that surgical
margin width is of limited influence on survival has also contrib-
uted to this development.28,35
In the present study, patients that underwent a caudate lobec-
tomy often presented with initially unresectable metastases as a
result of vascular proximity. Combined vascular resection was
frequently performed, but surgical morbidity was not increased
compared with a control group without a caudate lobectomy.
Recurrences occurred in a similar proportion as in patients
without caudate lobe involvement, although patients with a
caudate lobe resection more often presented with R1 resections.
Khan et al. found similar results, confirming that patients with
metastases in the caudate lobe can be offered a similar short-term
outcome as other patients with CLM.34 Others suggested a
decreased survival in the case of caudate lobe involvement as a
result of a early spreading of tumour cells through direct venous
drainage in the vena cava.36,37 This was, however, not confirmed in
the present cohort.
In conclusion, an extended left hepatectomy for CLM is tech-
nically challenging with a high risk of microscopically involved
margins and tumour recurrence. However, in a multidisciplinary
setting, it may provide significant long-term survival. Owing to
the complexity of this procedure with a high morbidity rate and
the so-called volume–outcome relationship in this field, patients
should be referred to specialized liver surgery centres.
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